Biden admin. proposes coverage for weight-loss drugs by Medicare, Medicaid
Share on Facebook Share on Twitter Under a new rule the Biden administration proposed on Tuesday, millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or
Biden wants Medicare, Medicaid to cover pricey weight loss drugs such as Wegovy
The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.
Weight-loss drug Zepbound might help manage heart failure
Zepbound, a drug used to help patients lose weight and manage diabetes, may also help those with heart failure, a new trial shows.
Medicare moves to expand coverage for weight-loss drugs Wegovy, Zepbound
The Biden administration is proposing a major expansion of how Medicare and Medicaid cover the weight-loss drugs Wegovy and Zepbound.
Biden wants to cover weight loss meds. RFK Jr. would rather we just eat better.
The Biden administration proposed expanding coverage of weight loss medication to Medicaid and Medicare recipients. RFK Jr. may not be such a fan.
White House Proposes Big Expansion of Medicare, Medicaid Coverage of Obesity Drugs
More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the proposal.
How to preserve muscle mass on weight-loss drugs like Wegovy
There is some debate as to whether GLP-1 agonist drugs like Wegovy can lead to unhealthy muscle mass loss in addition to general weight loss. Is this a real concern, and if so, how can a person maintain their muscle mass on GLP-1 drugs?
Biden proposes Medicare, Medicaid cover pricey weight-loss drugs for obese Americans
Millions of Americans could soon have access to weight-loss medications that some have called "miracle drugs."
What to Know About Biden’s Plan for Weight-Loss Drugs, Medicaid and Medicare
The Biden administration proposed a rule for Medicare and Medicaid to cover the costs of weight-loss drugs for millions of Americans with obesity.
Biden’s plan for Medicare coverage of weight-loss drugs would drive up costs by billions of dollars
President Joe Biden’s proposal to have GLP-1 weight-loss drugs such as Wegovy, Ozempic, Zepbound and Mounjaro covered by Medicare and Medicaid would help tackle the public-health crisis of obesity, but it would raise the costs for the government programs by billions of dollars per year.
Zepbound Slashes Diabetes Risk in Obese Users
WEDNESDAY, Nov. 27, 2024 (HealthDay News) -- The cutting-edge weight-loss drug Zepbound can protect obese people from developing type 2 diabetes, a new clinical trial has found. Zepbound reduced the ...
The Ultimate Pharmaceutical Stock to Buy With $1,000 Right Now
Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue ...
The FDA Can’t Decide Whether Zepbound Is in Shortage. It’s Good News for Hims & Hers Stock.
The Food and Drug Administration told a federal judge Thursday that it needs more time to reconsider whether Eli Lilly’s ...
Eli Lilly’s Stock Poised for Growth Amid Potential CMS Coverage for Zepbound
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...
Cheap Ozempic? How millions of Americans with obesity may get access to costly weight-loss drugs
Millions of obese Americans would get access to popular weekly injectables that would help them shed pounds quickly if a $35 ...
Investor's Business Daily on MSN1d
Amgen Crashes After Weight-Loss Drug Only Meets Eli Lilly's Zepbound
Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...
BioPharma Dive1d
Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark
Shares in Amgen fell by double digits Tuesday on long-awaited results for the company’s monthly MariTide shot, which is ...